Maplight Therapeutics (NASDAQ:MPLT) Director Sells 21,262 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 21,262 shares of the business’s stock in a transaction on Thursday, January 29th. The shares were sold at an average price of $18.55, for a total transaction of $394,410.10. Following the transaction, the director owned 371,885 shares in the company, valued at $6,898,466.75. The trade was a 5.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Maplight Therapeutics Stock Down 4.8%

Maplight Therapeutics stock traded down $0.89 during midday trading on Friday, hitting $17.69. 259,632 shares of the stock were exchanged, compared to its average volume of 186,272. The stock’s 50-day simple moving average is $17.62. Maplight Therapeutics, Inc. has a 52-week low of $12.24 and a 52-week high of $21.55. The company has a market capitalization of $802.60 million and a PE ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Wall Street Analyst Weigh In

MPLT has been the subject of a number of recent research reports. Morgan Stanley began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set an “overweight” rating and a $34.00 price target for the company. Weiss Ratings began coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Leerink Partners started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 target price on the stock. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Finally, Wall Street Zen raised Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.